Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 9/20 | 0.46 |
| ▸ | ALPI | P09923 | 8/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591566 | 0.72 | MCL1 (0.53) | MCL1 | |
| SCHEMBL3584846 | 0.69 | ALPL (0.40) | ALPLALPI | |
| SCHEMBL3584542 | 0.68 | ALPL (0.38) | ALPLALPI | |
| SCHEMBL7518597 | 0.64 | ALDH1A1 (0.43) | ALPLALPI | |
| SCHEMBL6631119 | 0.64 | ALPL (0.55) | ALPLALPIMAOA | |
| SCHEMBL3585931 | 0.64 | KMT2A (0.43) | — | |
| SCHEMBL5730960 | 0.61 | ALPI (0.56) | ALPLALPIMAOA | |
| SCHEMBL11227296 | 0.61 | MCL1 (0.68) | ALPLALPIMCL1MAOA | |
| SCHEMBL27587212 | 0.60 | ALPL (0.51) | ALPLALPIMCL1MAOA | |
| SCHEMBL1494398 | 0.58 | MAPT (0.46) | ALPLALPIMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732435-B2 | Chromone derivatives useful as antagonists of VR1 receptors | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | CULSHAW ANDREW JAMES | 2008-12-18 | — | — | US | disclosed |
| EP-1963334-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065888-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | VRK1, VRK2, ARRB1 | ALPL 4331/4885ALPI 2492/4885MCL1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.